Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01358266 · ClinicalTrials.gov registry record · Phase 3
Study Assessing Double-masked Uveitis Treatment
A Phase 3 study, sponsored by Santen.
- Completed
- Registry status
- Phase 3
- Development phase
- 592
- Enrollment target
NCT01358266 is a Phase 3 study that has completed, run by Santen. The registered enrollment target is 592 participants.
The verdict
NCT01358266, a Phase 3 study, has completed, sponsored by Santen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 592 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
Interventions
- DRUG DE-109 44 ug
- DRUG DE-109 440 ug
- DRUG DE-109 880 ug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 592 participants |
| Start Date | 2011-05 |
| Est. Completion | 2016-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01358266
The ClinicalTrials.gov registry entry for NCT01358266 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 592 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Santen, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which DE-109 44 ug is the first listed.
NCT01358266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01358266 about?
NCT01358266 is a clinical study titled "Study Assessing Double-masked Uveitis Treatment". The purpose of this study is to evaluate the safety and efficacy of intravitreal injections of DE-109 ophthalmic solution.
What is the current status of trial NCT01358266?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 592 participants. The study started on 2011-05. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01358266?
The interventions under investigation include: DE-109 44 ug (DRUG), DE-109 440 ug (DRUG), DE-109 880 ug (DRUG).
Who is sponsoring clinical trial NCT01358266?
This trial is sponsored by Santen, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.